Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
Australian Pension Funds Boost Currency Hedging as Aussie Dollar Strengthens 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
